Shared care arrangements for specialist drugs in the UK: the challenges facing GP adherence

Sarah Crowe,1 Judith A Cantrill,2 Mary P Tully2

ABSTRACT
Objective To explore the challenges facing GPs’ adherence to shared care arrangements for specialist drugs.

Design A qualitative study using semistructured interviews; data analysed using the ‘framework’ approach aided by QSR N-Vivo 2.0.

Setting Three Primary Care Trusts (PCTs) within one Strategic Health Authority (SHA) in the North West of England.

Participants 47 semistructured interviews were conducted with a range of Practice, PCT and SHA staff and other relevant stakeholders.

Results GPs faced multiple challenges in adhering to shared care arrangements for specialist drugs. Psychiatric patients were given as an example where such arrangements were perceived as particularly difficult to maintain, with patient non-compliance a contributory factor. GP uncertainty and confusion surrounded the sharing of test results between primary and secondary care, and was felt to give rise to test duplication and omission. Of particular concern to GPs was the lack of compliance of practice and hospital colleagues with these arrangements, and the dependence they placed on specialists’ responses to requests for advice.

Conclusion This study provides evidence of the numerous challenges facing GP adherence to shared care arrangements. Such challenges need to be overcome if the issues of test duplication and omission are to be addressed, and GPs’ future acceptance of shared care arrangements encouraged.

INTRODUCTION
In 2007, the Royal College of General Practitioners produced an information sheet detailing the concept of ‘Shared Care’.11 Shared care has been defined as ‘the joint participation of hospital consultants and general practitioners in the planned delivery of care for patients with a chronic condition, informed by an enhanced information exchange over and above routine discharge and referral letters’.12 Such integration and regular liaison have long been advocated in UK guidelines for the management of asthma13 and dementia.4 Integrated care schemes for chronic conditions such as diabetes have been shown to be as effective as conventional outpatient clinic attendance in clinical and economic terms.5 6 Patients found this type of care convenient and possibly cost-saving,5 and were more likely to select integrated care in the future.6 In 2008, Cheung et al14 went further by suggesting that the majority of patients with diabetes receiving routine GP management for their condition did not need to regularly attend a specialist clinic. Nurse-led shared care programmes have also been shown to be effective, with McHugh and colleagues reporting how an educational intervention led to an improvement in patient care for those awaiting coronary artery bypass grafting (CABG).5

Primary–secondary integration, via shared care, has promoted the prescribing of specialist drugs in the community for the treatment of certain chronic conditions. Specialist medicines have been defined as ‘medicines, usually of high-cost, that are initiated only by a hospital doctor and require complex prescribing and/or therapeutic monitoring arrangements not normally undertaken in general practice’.9 GPs have been found to be generally dissatisfied with shared care arrangements for prescribing specialist medicines, especially around issues of clinical responsibility associated with prescribing and often monitoring.9 With enhanced services and practice-based commissioning (PbC) aiding a shift in healthcare from secondary to primary care for some specialist services in the UK,10 GPs’ ability and willingness to adhere to shared care arrangements has gained prominence. This study explores the challenges faced by GPs attempting to adhere to shared care arrangements for specialist drugs.

METHODS
Study design
This study was a three-stage sequential design. Stage 1 aimed to seek the perspectives of a wide range of practice staff within three Primary Care Trusts (PCTs) in one Strategic Health Authority (SHA) which was chosen for its convenience in the North West of England. Stage 2 sought additional information and further explanation in a similar way (as discussed below) from the pharmaceutical adviser/prescribing lead in each PCT (July to August 2005, n=3) as well as from stakeholders with a vested interest in the primary secondary care interface (Stage 3, October 2005 to January 2006, n=8). These individuals included the local hospital’s chief pharmacist and medical director, and members of interface groups including the SHA Interface Prescribing Group (a group specifically set up to address prescribing issues which occur at the interface), for example.

For Stage 1, 342 letters were distributed to staff in 26 general practices (via their practice managers), inviting them to participate in a face-to-face semistructured interview on how primary–secondary care interface issues were perceived to have impacted on GP prescribing. Of the 73 staff who responded, 36 were purposively selected to include a GP(s) (n=14) and one or more other staff members per practice (see
Analysis

Detailed and repeated reading of transcripts was conducted to identify recurrent themes common to interviewees working in practices (practice managers, doctors, receptionists and nurses). PCT staff and stakeholders’ perspectives were used to provide further understanding on these emerging themes. Main and subthemes were developed as part of the five-stage ‘framework’ approach, using constant comparison. Themes were continually refined and applied systematically to the whole dataset using computerised software QSR N-Vivo version 2.0. Consistencies and differences were identified, apparent ‘negative cases’ examined, and evolving explanations further refined and tested. In the quotes presented below, words in parenthesis and ellipses (...) were added by the authors; the former to clarify meaning, the latter to indicate the removal of unrelated text. Participants’ occupations or roles were identified: DR, doctor; PM, practice manager; NU, nurses; AD, administrative staff; PA, pharmaceutical adviser; PL, prescribing lead; ST, stakeholder. An identification code was assigned to all participants to reflect the order of interviews.

RESULTS

Four inter-related themes central to understanding the challenges facing GPs’ adherence to shared care arrangements for specialist drugs emerged: GPs’ ambivalence surrounding the management of psychiatric patients; the sharing of test results; complying with the shared care arrangement; and dependence on specialist advice.

GPs’ ambivalence around the management of psychiatric patients

The patient group most commonly referred to by interviewees was psychiatric patients. Shared care arrangements for these patients were perceived by GPs, PCT staff and stakeholders as being particularly difficult to maintain. Patient non-adherence was reported with therapeutic drug monitoring attendance at GP practices. This was believed to contribute to a deterioration of the patient’s condition and the consequent takeover of their care by the hospital (DR11, box 1). One stakeholder, who reflected on her role as chief pharmacist of the acute mental health trust, felt that psychiatric patients often required more consultation time than other patient groups, and ‘some individual GPs’ did not have a good understanding of mental health issues (ST1, box 1).

Sharing of test results

The sharing of test results was illustrated as problematic, most commonly by discussing lithium and disease-modifying anti-rheumatic drugs (DMARDs). One GP expressed difficulty in altering the lithium dosage without the latest hospital results (DR12, box 2). A colleague who shared his view explained how she was often unaware that such tests had been completed by the hospital and relied solely on the patient to inform her. She felt the hospital’s inability to inform the practice contributed to test duplication (DR11, box 2). Such duplication also occurred in other practices, where the electronic link between the hospital’s and practice’s computer systems was not sufficiently advanced to allow the transfer of lithium results. Although the capabilities of such systems were outside the scope of this study, staff in another practice in a different PCT appeared to only have access to test results which they had requested themselves. One GP regarded their behaviour as appropriate, explaining how she made the assumption that tests had not been conducted if not reliably informed by the hospital (DR15, box 2). Supporting both views, one stakeholder felt the aforementioned technical inabilities, together with the lack of a shared care protocol for lithium, had exacerbated the current situation thus potentially giving rise to both test duplication and omission (ST1, box 2).

Practice and PCT staff supported this view: ‘there must be occasions where you’re assuming the other one (hospital) is doing it, and they are assuming you (GP) are doing it, and no one is actually doing it’ (DR12). With patients perceived as ‘falling between primary and secondary care,’ local PCT initiatives (which financially rewarded practices that sought hospital test results) were felt to have brought about ‘pretty good improvements ... even with that patient set (psychiatric)’ (PA5). However, GPs appeared reluctant to contact secondary care directly, highlighting the perceived time and effort required: ‘You have got to weigh up in a busy day how much work you want to put into following this up’ (DR29). This lack of results sharing was acknowledged to have possible future implications for secondary care prescribers, with ‘some practices refusing to take on patients who, maybe in the past, they would have been willing to take on’ (PA3).

GP uncertainty and confusion also surrounded the sharing of test results in relation to DMARD monitoring and prescribing. One GP, who had recently completed his training in hospital, expressed doubts about whether secondary care monitoring had

Table 1

<table>
<thead>
<tr>
<th>PCT no</th>
<th>Practice no</th>
<th>Doctor</th>
<th>Practice manager</th>
<th>Nurse</th>
<th>Administrative staff</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>1</td>
<td>DR1</td>
<td>PM2</td>
<td>NU3</td>
<td>AD4</td>
</tr>
<tr>
<td>2</td>
<td>2</td>
<td>DR5</td>
<td>PM6</td>
<td>NU7</td>
<td>AD8</td>
</tr>
<tr>
<td>3</td>
<td>3</td>
<td>DR9</td>
<td>PM10</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>4</td>
<td>4</td>
<td>DR11</td>
<td>PM13</td>
<td>NA</td>
<td>AD14</td>
</tr>
<tr>
<td>5</td>
<td>5</td>
<td>DR15</td>
<td>PM16</td>
<td>NU17</td>
<td>AD18</td>
</tr>
<tr>
<td>6</td>
<td>6</td>
<td>DR19</td>
<td>PM20</td>
<td>NU21</td>
<td>AD22</td>
</tr>
<tr>
<td>7</td>
<td>7</td>
<td>DR23</td>
<td>PM26</td>
<td>NU27</td>
<td>NA</td>
</tr>
<tr>
<td>8</td>
<td>8</td>
<td>DR28</td>
<td>PM31</td>
<td>NU32</td>
<td>AD33</td>
</tr>
<tr>
<td>9</td>
<td>9</td>
<td>DR34</td>
<td>PM35</td>
<td>NA</td>
<td>AD36</td>
</tr>
</tbody>
</table>
been carried out in accordance with the agreed shared care arrangement and explained how such uncertainty had given rise to some prescribing concerns (DR12, box 2). The importance of accurate monitoring and initial patient stability was illustrated in many quotes, with appreciation shown for any advice and guidance offered (DR15, box 2).

**Complying with the shared care arrangement**

Both practice and hospital compliance with agreed shared care arrangements were questioned by GPs. One GP hesitated to accept such arrangements, explaining how responsibility would then be transferred to him for the entire practice staff monitoring and prescribing of the specialist drug. As patients were entitled to see any GP in his practice, he could not guarantee that other GPs would adhere to such an arrangement for a number of reasons (DR23, box 3). These included infrequent GP use of specialist drugs and his inability to highlight potentially dangerous situations to fellow GPs in the future. According to him, a practice computer system which could ‘automatically flag up an error message or a warning message to say “Look out, this patient is on this drug, they shouldn’t be” (DR23) would help eliminate this problem and potentially ensure GP compliance with shared care arrangements. GPs in other practices did not appear to consider this a problem, explaining how GP communication was ‘usually (done) through the notes or on the computer’ (DR29) within the practice. One GP explained how ‘reminders’ or ‘little messages’ could be put on to the ‘prescribing screen’ (DR30) to facilitate compliance with shared care arrangements. Despite this, he acknowledged how little he had used the computer as a means of communication, showing dependence on other practice staff to recognise and report abnormal levels that required immediate GP action (DR30, box 3).

In relation to hospital compliance with shared care arrangements, one GP expressed her belief that a higher number of tests had been carried out than had previously been agreed. She recalled how the shared care arrangement was ‘not working at the moment’ because consultants were ‘unnecessarily’ repeating blood tests recently conducted by her practice (DR19, box 5). Another GP, who also shared this view, took reassurance from blood tests recently conducted by her practice (DR19, box 3). The importance of relying on specialist advice was acknowledged how little he had used the computer as a means of communication, showing dependence on other practice staff to recognise and report abnormal levels that required immediate GP action (DR30, box 3).

**Dependence on specialist advice**

Much dependence was placed on the response of specialists to GP requests for advice. One GP illustrated this by highlighting the effort required in addressing methotrexate irregularities, in terms of referring to supporting information, and seeking specialist advice (DR25, box 4). Similar evidence was provided by a nurse in a different practice, who explained how reliance had been placed on hospital staff to inform them about what they should ‘do in the meantime, while they are waiting’ for specialists to see three patients who had suffered adverse effects from a specialist drug (NU32, box 4).

**DISCUSSION**

Shared care arrangements for specialist drugs have many far-reaching benefits for patients and throughout the National Health Service (NHS). In this study, GPs faced multiple challenges...
Box 3 Complying with the shared care arrangement

‘the worry I’ve got is they will send a letter that says ‘Will you please continue this drug, this is the monitoring you need, and these are the indications for why you should stop that’ … We have got seven doctors here. That information lands on my desk as a letter and I’m sitting there thinking right, so how do I make it safe so that I know that if these conditions are met, somebody in the practice will know to stop the tablets knowing full well that it is not a tablet we use regularly … it was a problem that we pose in the practice’ (DR23)

‘I mean if they were on gold injections and their neurophils dropped below such and such you are going to stop it … it wouldn’t come up on the computer but things like that would be followed up say by the nurse’ (DR30)

‘if we have been doing the monitoring every two months say … and then they go to the clinic on month four, the consultant will always do the bloods even if they don’t need doing … we have done them the week before’ (DR19)

in adhering to these shared care arrangements, the most important being their ambivalence around the management of psychiatric patients, the sharing of test results, compliance with the shared care arrangement and their dependence on specialist advice. Drawing comparisons with existing literature, one of the core issues for GPs was the sharing of test results. Confusion over the monitoring and treatment of patients with mental illness was particularly apparent. A joint report from the Royal Colleges of Physicians and Psychiatrists notes how patient non-adherence to treatment or health advice necessitates referral to a mental health team. This leaves the stakeholder’s view of how some GPs are not skilled in mental health and would like to refer all patients back to hospital vulnerable to criticism. In addition to the technical inabilities of both hospital’s and practice’s computer systems mentioned in this study, specialists were portrayed as failing to meet their perceived obligations to disseminate the results of tests conducted. Crucially, such breaches brought issues of test duplication and patient inconvenience to the fore and raise important concerns over patient safety, and cost to both the patient and the NHS, of this test repetition or more significantly from its acknowledged absence. This study also shows how the introduction of a PCT initiative potentially encouraged test duplication.

The National Programme for Information Technology (NPfIT) being delivered by the agency Connecting for Health in the UK supports the provision of better, safer care, by enabling clinical information to be securely shared between different parts of the local NHS. However, with implementation of the NHS Care Record Service (CRS) still at an early stage and concerns voiced at Connecting for Health’s unrealistic timetable, the risk to patients’ safety continues to grow. There also appears to be a need for an improved approach to communication that connects frontline staff with each other and with patients. In this way, more support could be offered to GPs addressing specialist drug irregularities, psychiatric patients’ non-compliance, and ensuring colleague compliance with shared care arrangements. While computerised support might be necessary, this study also shows how it may not be sufficient to obtain commitment from relevant parties to making the process work. GP involvement in the development of shared care arrangements from the onset is likely to be beneficial. Both GPs’ and stakeholders’ accounts gave the impression that such issues had the potential to influence future acceptance of shared care arrangements by primary care. This is an important finding, with Lord Darzi’s report High Quality Care For All reinforcing the message that more care could, and should, be provided closer to people’s homes. With many UK regions planning to make this vision a reality, it is clear from this study that better communication between primary and secondary care is essential.

This study had inherent limitations, one being self-selection; it is possible that primary—secondary interface issues interested participants more than non-volunteers. This, together with the fact that the study was undertaken within a single SHA in England, limited the generalisability of findings. However, common themes did emerge, and thematic saturation was satisfactorily achieved. This study would also have benefited from complementary interviews with patients, hospital clinicians and discharge liaison nurses, increasing the number of alternative viewpoints and strengthening the conclusions drawn. One of the main strengths of this study was the breadth of participants interviewed, some of whom had recent or current experience in secondary care. Different perspectives from both within and between practices, PCTs and different primary—secondary interface groups helped ensure the credibility and trustworthiness of study findings. The sequential approach also enhanced the entire study by allowing initial data analysis to guide efficient sample choice.

CONCLUSION

We recommend that policy makers take into account the complex picture presented here, and the multiple challenges facing GP adherence to shared care arrangements for specialist drugs. The core issue of ‘results sharing’ needs to be acknowledged and addressed if future problems relating to test duplication for both patients and hospitals are to be avoided. Such a finding gains increasing emphasis with the Departments of Health’s Creating a patient-led NHS and subsequent Commissioning a patient-led NHS documents highlighting how the patient’s experience is paramount and their choice integral to the way services are delivered. With the Care Quality Commission supporting the referral of patients to primary-care-based specialist monitoring clinics, we suggest that PCTs review their shared care arrangements for specialist drugs between primary and secondary care in light of our findings.

Box 4 Dependence on specialist advice

‘I think methotrexate is maybe not a bad example … I think a minor irregularity … would perhaps take some looking up and see what this might represent and if you felt that there (are) sort of particular concerns … phoning up somebody and saying “Look the patient has this problem with the medications, I’m not sure if they should be on them any more … Should they stop? Will you see them? What can we do in the meantime whilst she is waiting for you to review her?” (DR25)

‘we had quite an upset with myelosil. Three patients went really funny and ended up in Accident and Emergency so you have to discuss then you know, what you are going to do about the drugs?, refer them back to the consultant but also in touch with the Rheumatoid nurse’ (NU52)
Acknowledgements We would like to thank all participants who generously gave up their time for this study.

Funding This study was funded by the University of Manchester as part of a PhD programme.

Competing interests None.

Ethics approval Ethics approval was provided by the North Manchester Research Ethics Committee (Ref no 04/Q1406/99).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES